Kymriah CAR-T Cell Therapy: What the 2026 Trial Data Shows
Nearly a decade after its FDA approval, Kymriah’s long-term trial data is finally in. This article breaks down what 2026 results from the ELIANA, JULIET, and ELARA trials reveal about durability and safety of CAR-T cell therapy with Kymriah.
Regenerative Medicine Centers: The 2026 Standards That Matter
As the regenerative medicine market surges toward $360 billion by 2034, patients face growing confusion when choosing a provider. This guide moves beyond marketing claims to explain the FDA rules, FACT accreditation, and legal precedents that define legitimate regenerative medicine centers in 2026.